Association of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3) with socio-demographic factors and metastases site in women with metastatic breast cancer in Albania

Adrian Hoti, Edmond Gashi, Fationa Kraja, Agim Sallaku

Abstract

Aim: The aim of our study was to assess the association of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) with socio-demographic factors and metastases site in women diagnosed with metastatic breast cancer in post-communist Albania.

Methods: A case-series study was carried out during the period January 2010 – September 2017 including 110 female patients diagnosed with breast cancer with metastases at the Oncology Service of the University Hospital Centre “Mother Teresa” in Tirana, the Albanian capital. Of these, 57 (51.8%) patients had evidence of hepatic metastases, whereas the reaming 53 (48.2%) patients had metastases in the bones and/or in the lungs. CEA and CA15-3 were measured at the time of diagnosis for all study participants. In addition, information on socio-demographic factors was collected. General linear model was used to assess the relationship of CEA and CA15-3 with covariates.     

Results: There was evidence of a significant correlation between CEA and CA15-3 levels (Spearman’s rho=0.59, P<0.001). Upon simultaneous adjustment for all covariates, mean values of CEA and CA15-3 were significantly higher in patients with metastases in the bones and/or in the lungs compared with their counterparts with metastases in the liver. Also, CA15-3 levels were significantly higher in younger patients compared with their older counterparts.

Conclusion: This study provides valuable evidence on selected correlates of CEA and CA15-3 in Albanian female patients diagnosed with metastatic breast cancer. Oncologists and other health professionals in Albania, as well as decision-makers and policymakers should be aware of the burden and risk factors of breast cancer among women in this transitional society.         

 

 

Keywords

Albania, bone metastases, breast cancer, cancer antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), hepatic metastases, lung metastases, oncology, tumours, tumour markers.

Full Text:

PDF

Cite this article

References

Lu C, Sun H, Huang J, Yin S, Hou W, Zhang J, et al. Long-Term Sleep Duration as a Risk Factor for Breast Cancer: Evidence from a Systematic Review and Dose-Response Meta-Analysis. Biomed Res Int 2017;2017:4845059. DOI: 10.1155/2017/4845059.

Anderson BO, Lipscomb J, Murillo RH, Thomas DB. Breast cancer (in Cancer: Disease Control Priorities. Gelband H, Jha P, Sankaranarayanan R, Horton S, editors; 3rd edition). The International Bank for Reconstruction and Development / The World Bank, Washington, DC, USA; 2015.

Colditz GA. Epidemiology and prevention of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:768-72.

Cappuccio FP, Cooper D, Delia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J 2011;32:1484-92.

Yildiz M, Oral B, Bozkurt M, Cobaner A. Relationship between bone scintigraphy and tumor markers in patients with breast cancer. Ann Nucl Med 2004;18:501-5.

Basuyau J, Blanc-Vincent M, Bidart J, Daver A, Deneux L, Eche N, et al. Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000. Br J Cancer 2003;89:S32-4.

Molina R, Barak V, Van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer—European Group on tumor markers recommendations. Tumor Biol 2005;26:281-93.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007: update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-91.

Champion L, Brain E, Giraudet AL, Le Stanc E, Wartski M, Edeline V, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer 2011;117:1621-9.

Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Database. Seattle, WA: IHME, University of Washington; 2017. http://www.healthdata.org (Accessed: December 17, 2017).

World Health Organization. Core Health Indicators in the WHO European Region. Copenhagen, Denmark; 2017.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics 2009. CA Cancer J Clin 2009;59:205-49.

European Society of Medical Oncology. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann Oncol 2007;18:ii5-8.

Zervoudis S, Peitsidis P, Iatrakis G, et al. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. J BUON 2007;12:487-92.

Suarez M, Perez-Castejon MJ, Jimenez A, Domper M, Ruiz G, Montz R, Carreras JL. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002;46:113-21.

Aide N, Huchet V, Switsers O, Heutte N, Delozier T, Hardouin A, Bardet S. Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun 2007;28:267-72.


DOI: 10.4119/UNIBI/SEEJPH-2017-178

Copyright (c) 2018 Adrian Hoti, Edmond Gashi, Fationa Kraja, Agim Sallaku

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.